Yetgin S, Yenicesu I, Cetin M, Tuncer M
Department of Pediatric Haematology, Ihsan Dogramaci Children's Hospital, Hacettepe University, 06100, Ankara, Turkey.
Leuk Lymphoma. 2001 Jun;42(1-2):83-8. doi: 10.3109/10428190109097679.
The aim of this study is to evaluate, for the first time serum levels of vascular endothelial growth factor (s-VEGF), and basic fibroblast growth factor (s-b FGF) in children with acute lymphoblastic leukemia (ALL), and its relation to clinical manifestations of the disease. Although VEGF and b FGF have been suggested to be reliable prognostic indicators and important tools for treatment approach in malignant haematopoietic and solid tumours, experience in childhood ALL has been limited to only one study on angiogenesis and urine b FGF. All 31 ALL patients included in the present study at the time of diagnosis and in remission, and all 10 control children had detectable serum levels of VEGF and b FGF. The median level of s-VEGF at the time of diagnosis was significantly lower than in the control group and at the time of remission (respectively p = 0.005, p = 0.0001). Twenty six of 31 patients had an increasing trend of s-VEGF levels in remission reaching control values compared with the levels obtained at diagnosis. S-b FGF median levels at the time of diagnosis were the same as those of the control group, significantly lower than the median s-b FGF values in remission (p = 0.001). In patients with lower platelet counts (< 50 x 10(9)/L) growth factors (VEGF and b FGF) were lower than in patients with higher platelet counts (p = 0.0009 and p = 0.002 respectively). In patients with hepatosplenomegaly (longitudinal size > 3 cm) b FGF levels were higher than patients without hepatosplenomegaly (P = 0.003). We concluded that the increment in both s-VEGF and s-b FGF in patients in remission may be related to the renewal of normal haematopoiesis. The increase in s-VEGF values in 26 out of 31 patients in remission compared to normal control values, may also suggest that there is clinical significance in ALL patients.
本研究的目的是首次评估急性淋巴细胞白血病（ALL）患儿血清血管内皮生长因子（s-VEGF）和碱性成纤维细胞生长因子（s-bFGF）水平，并探讨其与疾病临床表现的关系。虽然VEGF和bFGF已被认为是恶性造血肿瘤和实体瘤可靠的预后指标及治疗的重要工具，但儿童ALL的相关经验仅限于一项关于血管生成和尿bFGF的研究。本研究纳入的31例ALL患者在诊断时和缓解期，以及10例对照儿童均检测到血清VEGF和bFGF水平。诊断时s-VEGF的中位数水平显著低于对照组和缓解期（分别为p = 0.005，p = 0.0001）。31例患者中有26例缓解期s-VEGF水平呈上升趋势，与诊断时相比达到对照值。诊断时s-bFGF的中位数水平与对照组相同，显著低于缓解期s-bFGF的中位数水平（p = 0.001）。血小板计数较低（< 50×10⁹/L）的患者生长因子（VEGF和bFGF）低于血小板计数较高的患者（分别为p = 0.0009和p = 0.002）。有肝脾肿大（纵向尺寸> 3 cm）的患者bFGF水平高于无肝脾肿大的患者（P = 0.003）。我们得出结论，缓解期患者s-VEGF和s-bFGF的升高可能与正常造血的恢复有关。31例缓解期患者中有26例s-VEGF值相对于正常对照值升高，这也可能表明在ALL患者中具有临床意义。
